Oral Tirzepatide Consumer Safety Investigation

Shub Johns & Holbrook launches an investigation into oral tirzepatide products after some reports indicate that online telehealth companies and pharmacies had deceived its consumers as to the effects of the supposed GLP-1 tablets.

Some tirzepatide products like “oral tirzepatide”, “tirzepatide ODT”, “oral dual agonist” and “oral GLP-1/GIP pill” are marketed by manufacturing companies and several telehealth facilities and pharmacies as alternatives to injectable GLP-1 medication like Mounjaro or Zepbound, or the consumable Rybelsus. Some reports however indicate that these oral tirzepatide products pushed by these organizations may not contain the active ingredients necessary to be classified as an oral tirzepatide.

This not only deceives consumers into thinking that they are purchasing a safe and functional alternative to name-brand tirzepatide products recommended by healthcare professionals, but may also lead to potential health risks for some consumers.

Telehealth websites, and popular GLP-1 brands selling these allegedly misrepresented products include:

If you have purchased an “oral tirzepatide” product from any of these companies, or another company you believe may also be deceiving consumers, let us know! Fill out our form to join the investigation today!